382 related articles for article (PubMed ID: 23067528)
1. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
[TBL] [Abstract][Full Text] [Related]
2. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography (18FDG-PET) in the detection of medullary thyroid carcinoma metastases.
Mucha SA; Kunert-Radek J; Pomorski L
Endokrynol Pol; 2006; 57(4):452-5. PubMed ID: 17006852
[TBL] [Abstract][Full Text] [Related]
4. Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
Marzola MC; Pelizzo MR; Ferdeghini M; Toniato A; Massaro A; Ambrosini V; Fanti S; Gross MD; Al-Nahhas A; Rubello D
Eur J Surg Oncol; 2010 Apr; 36(4):414-21. PubMed ID: 20100647
[TBL] [Abstract][Full Text] [Related]
5. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
6. Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K; Khan S; Taghizadehasl M; Palazzo F; Frilling A; Todd JF; Al-Nahhas A
Hell J Nucl Med; 2015; 18(1):19-24. PubMed ID: 25679074
[TBL] [Abstract][Full Text] [Related]
7. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A
Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773
[TBL] [Abstract][Full Text] [Related]
8. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer.
Skoura E; Rondogianni P; Alevizaki M; Tzanela M; Tsagarakis S; Piaditis G; Tolis G; Datseris IE
Nucl Med Commun; 2010 Jun; 31(6):567-75. PubMed ID: 20335822
[TBL] [Abstract][Full Text] [Related]
9. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
[TBL] [Abstract][Full Text] [Related]
10. The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.
Rubello D; Rampin L; Nanni C; Banti E; Ferdeghini M; Fanti S; Al-Nahhas A; Gross MD
Eur J Surg Oncol; 2008 May; 34(5):581-6. PubMed ID: 17892923
[TBL] [Abstract][Full Text] [Related]
11. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.
Faggiano A; Grimaldi F; Pezzullo L; Chiofalo MG; Caracò C; Mozzillo N; Angeletti G; Santeusanio F; Lombardi G; Colao A; Avenia N; Ferolla P
Endocr Relat Cancer; 2009 Mar; 16(1):225-31. PubMed ID: 19004986
[TBL] [Abstract][Full Text] [Related]
12.
Souteiro P; Gouveia P; Ferreira G; Belo S; Costa C; Carvalho D; Duarte H; Sampaio IL
Endocrine; 2019 May; 64(2):322-329. PubMed ID: 30684230
[TBL] [Abstract][Full Text] [Related]
13. [FDG PET scan of metastases in recurrent medullary carcinoma of the thyroid gland].
Szakáll S; Bajzik G; Repa I; Miklovicz T; Dabasi G; Sinkovics I; Esik O
Orv Hetil; 2002 May; 143(21 Suppl 3):1280-3. PubMed ID: 12077916
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
Beuthien-Baumann B; Strumpf A; Zessin J; Bredow J; Kotzerke J
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1604-9. PubMed ID: 17435996
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
Ong SC; Schöder H; Patel SG; Tabangay-Lim IM; Doddamane I; Gönen M; Shaha AR; Tuttle RM; Shah JP; Larson SM
J Nucl Med; 2007 Apr; 48(4):501-7. PubMed ID: 17401085
[TBL] [Abstract][Full Text] [Related]
16. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
[TBL] [Abstract][Full Text] [Related]
17. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R
Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819
[TBL] [Abstract][Full Text] [Related]
19. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
20. Radioguided hepatic resection with
López-Gómez J; Medina-Ornelas S; Salazar-Álvarez MA; Álvarez-Bojórquez M; Zaragoza-Cruz N; Melchor-Ruan J; Álvarez-Cano A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(4):244-249. PubMed ID: 29754940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]